Novo Nordisk's hemophilia A treatment approved by FDA

10/16/2013 | PharmaTimes (U.K.)

The FDA approved the use of Novo Nordisk's recombinant coagulation factor VIII drug Novoeight, or turoctocog alfa, to prevent and treat bleeding associated with hemophilia A. The firm plans to commercialize the drug shortly after the expiration of a third-party patent in April 2015.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park